XNCR Q4 2020 Earnings — Xencor, Inc. Revenue & Financial Results | Market Cap Arena

XNCRXencor, Inc.

$890M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$42M+1090.4% YoY

Gross Profit

-$6M-14.6% margin

Operating Income

-$14M-32.7% margin

Net Income

-$14M-32.7% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

+18.3%

Cash Flow

Operating Cash Flow

$17M

Free Cash Flow

$13M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$703M

Total Liabilities

$131M

Stockholders' Equity

$572M

Cash & Equivalents

$164M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$42M	$4M	+1090.4%
Gross Profit	-$6M	-$24M	+74.4%
Operating Income	-$14M	-$31M	+55.2%
Net Income	-$14M	-$27M	+49.1%

Revenue Segments

License

$22M53%

Milestone

$12M30%

Royalty

$6M15%

Collaboration

$1M3%